A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 Following ALLO-647 Containing Conditioning Regimen in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced or metastatic clear cell renal cell carcinoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647 to define a Phase 2 dose.

开始日期2021-02-24

申办/合作机构

Allogene Therapeutics, Inc.

100 项与 ALLO-316 相关的临床结果

登录后查看更多信息

100 项与 ALLO-316 相关的转化医学

登录后查看更多信息

100 项与 ALLO-316 相关的专利（医药）

登录后查看更多信息

项与 ALLO-316 相关的文献（医药）

2023-09-01·Translational research : the journal of laboratory and clinical medicine

Rabies virus glycoprotein 29 (RVG29) promotes CAR-T immunotherapy for glioma

Article

作者: Chen, Zhengliang ; Zhang, Miaomiao ; Xu, Luxia ; Zhang, Fan ; Shi, Yan ; Jia, Shaochang ; Hu, Zhigang ; Ma, Ruiting ; Xu, Bin ; Lu, Xiao ; Liang, Junqing ; Long, Kaili ; Chen, Jiannan ; Du, Yu ; Zhang, Qi ; Wu, Heming ; Guo, Zhigang ; Li, Jun ; Xia, Mingyue ; Tang, Yong ; Ji, Feng

Chimeric antigen receptor T cell (CAR-T) therapy has limited efficacy for treating glioma because of the infiltrative nature of the blood-brain barrier (BBB) and T cell exhaustion. Conjugation with rabies virus glycoprotein (RVG) 29 enhances the brain-related efficacy of various agents. Here we assess whether RVG enhances the ability of CAR-T cells to cross the BBB and improves their immunotherapy. We generated 70R CAR-T cells (anti-CD70 CAR-T modified with RVG29) and validated their tumor-killing efficacy in vitro and in vivo. We validated their effects on tumor regression in a human glioma mouse orthotopic xenograft model as well as in patient-derived orthotopic xenograft (PDOX) models. The signaling pathways activated in 70R CAR-T cells were revealed by RNA sequencing. The 70R CAR-T cells we generated showed effective antitumor function against CD70⁺ glioma cells both in vitro and in vivo. 70R CAR-T cells were better able to cross the BBB into the brain than CD70 CAR-T cells under the same treatment conditions. Moreover, 70R CAR-T cells significantly promote the regression of glioma xenografts and improve the physical characteristics of mice without causing overt adverse effects. RVG modification enables CAR-T cells to cross the BBB, and stimulation with glioma cells induces 70R CAR-T cells to expand in a resting state. The modification of RVG29 has a positive impact on CAR-T therapy for brain tumors and may have potential in CAR-T therapy for glioma.

2023-07-01·Cancer immunology, immunotherapy : CII

Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia.

Article

作者: Cheng, Jiali ; Jin, Jin ; Zhu, Xiaojian ; Mu, Wei ; Zhu, Li ; Dai, Zhenyu ; Zeng, Yuhao ; Wang, Jue ; Yang, Yongkun ; Cai, Haodong ; Hu, Guang ; Mao, Xia ; Huang, Liang ; Zhou, Jianfeng ; Ge, Tong

BACKGROUND:

Acute myeloid leukemia (AML) treatment remains challenging. CD70 was reported as a promising AML-specific antigen. Preclinically, CAR T-cell with single-chain-variable fragment (scFv) or truncated CD27 targeting CD70 has been reported to treat AML. However, various disadvantages including spontaneous exhaustion, proteinase-mediated loss of functional receptors, and high immunogenicity, limited its further application to clinical settings. Alternatively, the single-variable domain on heavy chain (VHH), also known as nanobodies, with comparable binding ability and specificity, provides an optional solution.

METHOD:

We generated CD70 knocked-out novel nanobody-based anti-CD70-CAR T-cells (nb70CAR-T) with two different VHHs for antigen detection. Next, we detected the CD70 expression on primary AML blasts by flow cytometry and associated the efficacy of nb70CAR-T with the target antigen density. Finally, epigenetic modulators were investigated to regulate the CD70 expression on AML cells to promote the functionality of nb70CAR-T.

RESULTS:

Our nb70CAR-T exhibited expected tumoricidal functionality against CD70-expressed cell lines and primary AML blasts. However, CD70 expression in primary AML blasts was not consistently high and nb70CAR-T potently respond to an estimated 40.4% of AML patients when the CD70 expression level was over a threshold of 1.6 (MFI ratio). Epigenetic modulators, Decitabine and Chidamide can up-regulate CD70 expression on AML cells, enhancing the treatment efficacy of nb70CAR-T.

CONCLUSION:

CD70 expression in AML blasts was not fully supportive of its role in AML targeted therapy as reported. The combinational use of Chidamide and Decitabine with nb70CAR-T could provide a new potential for the treatment of AML.

2022-07-18·Cancer research

Antitumor CAR T-cell Screening Platform: Many Are Called, but Few Are Chosen

Communications

作者: Adotévi, Olivier ; Galaine, Jeanne

Abstract:

Treatment with T cells expressing chimeric antigen receptors (CAR) is a promising anticancer therapy. However, this approach has several limitations and has not yet been effectively applied to treat solid tumors. The study by Panowski and colleagues represents the first comparative analysis of multiple single chain fragment variable (scFv)-based anti-CD70 CAR T-cell clones for the development of a clinical product to treat renal cell carcinoma (RCC). Despite the risk of T-cell fratricide due to CD70 expression on T cells, CD70 CAR T cells were produced successfully thanks to the protective CD70 masking phenomenon. Two distinct classes of CAR T cells were identified with different memory phenotypes, activation statuses, and cytotoxic activity. CD70 CAR T cells presented high cytotoxic activity against RCC both in vitro in RCC cell lines and in vivo in patient-derived xenograft mouse models. The off-target effects expected on the lymphoid compartment were confirmed by tissue cross-reactivity staining and in a cynomolgus monkey preclinical model with CD3-CD70 bispecific antibody treatment. The efficacy and the toxicity profile of the lead CD70 CAR T-cell candidate instigated the researchers to proceed with upscaled clinical production. This article emphasizes the influence of the scFv of the CARs on their efficacy:toxicity balance. Ultimately, they successfully managed to develop a highly effective CAR T-cell candidate to treat a solid tumor by an allogeneic approach, thereby overcoming two major hurdles to broaden application of CAR T-cell therapy.See related article by Panowski et al., p. 2610

项与 ALLO-316 相关的新闻（医药）

2024-11-26

·今日头条

CAR-T杀疯了，致命癌种生存期从11个月暴增3倍，肿瘤缩小率达100%

一直以来，血液系统恶性肿瘤都是CAR-T细胞疗法的“主战场”，国内外有多款产品相继获批，而且临床疗效有目共睹。但实体瘤因其异质性、复杂的微环境等顽固壁垒，让诸多前沿免疫疗法折戟沉沙。但值得欣慰的是，近年来随着研究的不断深入，CAR-T细胞疗法在治疗实体瘤领域也取得了突破性进展。近期，全球知名期刊《Nature》发表了一项振奋人心的临床研究结果，改造后的CAR-T细胞疗法在治疗一种致死率近乎100%的致命脑癌方面，取得了显著疗效，其中一例患者更是奇迹般获得完全缓解，且近3年未复发！这一惊艳的研究成果，再次验证了CAR-T疗法在治疗恶性实体瘤方面的巨大应用潜力，为现有治疗方案无效的肿瘤患者带来了新的曙光与选择！一、致命脑瘤GD2-CAR T治疗后，生存期从11个月，飙升3倍，肿瘤缩小率可达100% H3K27M突变的弥漫性中线神经胶质瘤（DMG）起源于神经系统的中线结构，主要发生在儿童和年轻人中。脑桥弥漫性中线神经胶质瘤（也称为弥漫性内在性脑桥神经胶质瘤，DIPG）是儿童脑癌最常见的死亡原因，姑息放疗是标准治疗方法，即便配合化疗、靶向疗法等，预后仍然不理想，患者中位总生存期仅为11个月，5年总生存率低于1%。而脑干外（包括脊髓）DMG患者的中位总生存期为13个月。因此，迫切需要新的治疗方法，改善患者的预后。近期研究发现，GD2-CAR-T细胞疗法在治疗神经母细胞瘤的试验中，取得了令人惊叹的疗效。全球知名期刊《Nature》报道了“ 自体GD2-CART细胞，治疗DIPG和脊髓弥漫性中线胶质瘤（sDMG）的首次人体/首次儿童I期临床试验（NCT04196413） ”的惊艳数据。本次共入组13例中位年龄为15岁（范围4-30岁）的患者，其中 10例为脑桥弥漫性中线神经胶质瘤（即弥漫性内在性脑桥神经胶质瘤，DIPG）、3例脊髓弥漫性中线神经胶质瘤（sDMG）。这些患者均存在H3K27M突变，入组前至少4周完成标准一线放射治疗，未接受皮质类固醇治疗。最终11例患者接受了一次GD2-CART细胞静脉回输治疗，结果显示如下： 1、中位总生存期（OS）：所有患者的中位总生存期（OS）为确诊后20.6个月，其中，DIPG（脑桥弥漫性中线神经胶质瘤）患者的中位总生存期为 17.6个月，sDMG（脊髓弥漫性中线神经胶质瘤）患者的中位总生存期为 31.96个月。 ▼患者的生存期 ▲图源“nature”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除注：每条柱状图代表从诊断到第一次治疗的时间（黄色）、试验时间（蓝色）。 2、肿瘤体积缩小：4例患者的肿瘤体积大幅缩小，缩小幅度分别为52%、54%、91%、100% ，另有3例患者肿瘤小范围缩小。 ▼第一次GD2-CART治疗前后的肿瘤体积变化 ▲图源“nature”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除注：“星号（*）”表示在第一次GD2-CART细胞输注时，有记录的病情进展的患者。值得一提的是，其中2位脑桥弥漫性中线神经胶质瘤（DIPG）患者（患者007、患者010），在数据截止后，仍然存活，生存时间分别达到33个月、30个月，远超传统治疗11个月的中位总生存期！（一）010号患者CAR-T治疗后，症状缓解、肿瘤持续缩小，生存时间已达30个月 1、肿瘤持续缩小，完全缓解达30个月：该患者确诊为脑桥弥漫性中线神经胶质瘤（DIPG），在完成前期放疗后，通过影像学检查显示有进展或假进展的可能。在第一次GD2-CART细胞输注后的数月内，肿瘤体积持续缩小至完全反应。这种完全缓解在入组后30个月（数据截止时间）持续，并且仍在继续（详见下图）。 2、症状缓解：该患者在入组时，存在感觉和运动障碍，需要步行辅助（长距离使用轮椅）。在GD2-CART治疗后，不仅经历了影像学上的完全反应，同时伴有显著的临床改善，包括左侧听力改善，半脸、半身和味觉改善、运动协调性改善、步态改善至独立行走的程度。 ▼010号患者在基线时（治疗前），首次GD2-CART输注后3、5、16和29个月时，中脑、脑桥和延髓水平的肿瘤T2加权轴向MRI对比 ▲图源“nature”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除注：红色箭头表示T2信号异常。 ①在基线时（治疗前），可见肿瘤累及中脑（左侧＞右侧）、脑桥和延髓，且肿块遮挡第四脑室；CAR-T治疗3个月后消退。 ②治疗3个月时，随着脑干大小恢复正常，脑干周围脑脊液回流明显，大部分脑干的T2信号恢复正常。但T2信号仍异常，可能提示肿瘤仍存在于脑桥活检道区域周围（红色箭头），但5个月后消退。（二）006号患者CAR-T治疗7个月，肿瘤缩小91%、症状明显改善 1、肿瘤体积明显缩小：该患者确诊为脊髓弥漫性中线神经胶质瘤（sDMG），在第一次治疗时处于明显的临床和放射学肿瘤进展中，而在第一次GD2-CART细胞输注后7个月内，肿瘤体积显著缩小91% （详见下图）。 ▼006号患者在基线时（治疗前）、首次输注GD2-CART后2、6和9个月时的脊髓弥漫性中线神经胶质瘤的MRI图像对比 ▲图源“nature”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除注：红色轮廓表示T2信号异常（提示肿瘤）。 ①在基线时（治疗前），以T11/12脊髓水平为中心的肿瘤弥漫性地影响脊髓，并扩张脊髓以填满整个椎管，脊髓周围未观察到脑脊液（CSF）。 ②GD2-CART治疗后，脊髓肿瘤浸润逐渐改善，直至恢复正常大小且T2信号异常最小（红色箭头）。 2、症状显著改善：在第一次输注GD2-CART之前，该患者患有严重的截瘫、神经性疼痛、肠道和膀胱功能障碍。在输注GD2-CART后，且总体反应最好的时候（肿瘤缩小90%以上），患者疼痛明显改善，下肢功能改善，能够用拐杖行走。二、CAR-T疗法暴击多款实体瘤，打破难治性壁垒除了上文提到的脑瘤外，CAR-T细胞疗法在治疗肝癌、肾癌、胰腺癌、胃癌、结直肠癌等多款实体瘤方面，也彰显出了不俗的潜力。（一）肝癌：CAR-T治疗28天，肿瘤显著缩小超93%！ Ori-CAR-001是我国自研的一款针对GPC3的新一代自体嵌合抗原受体T细胞疗法，用于治疗难治性/复发性肝细胞癌（HCC）。在2021年美国临床肿瘤学会（ASCO）年会上，公布了GPC3CAR-T细胞疗法——Ori-CAR-001治疗复发/难治性肝细胞癌（HCC）的惊艳数据。本次共入组9例可评估疗效的肝细胞癌（HCC）患者，除1例患者为B期（中期）肝细胞癌（HCC）外，其余患者均为C期（晚期）肝细胞癌，这些患者既往治疗方案（包括化疗、TACE和靶向治疗）均失败。结果显示：客观缓解率（ORR）达到44.4%，疾病控制率（DCR）高达77.8%。其中，3例达到疾病稳定（SD）,4例患者获得部分缓解（PR）。 ▲图源“ASCO”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除 1、007号患者CAR-T治疗后，肿瘤缩小＞80% 值得一提的是，007号患者在CAR-T细胞输注后1个月，肿瘤体积显著缩小80%以上，且部分缓解（PR）持续6个月以上，截至2021年6月，该患者的疾病控制已超过8个月！ 2、012号患者CAR-T治疗后，肿瘤近乎消失、AFP骤降此外，012号患者也表现出良好的肿瘤反应，该受试者患有晚期弥漫性大块肝细胞癌，在放射治疗、靶向药物和12次TACE治疗失败后加入了本研究。该患者在CAR-T细胞输注后第28天，靶肿瘤病灶从133mm（治疗前最大肿瘤直径），显著缩小至9mm（CAR-T治疗28天），肿瘤减小率超过93%！并在CAR-T治疗第88天， MRI扫描显示肿瘤几乎完全消失（详见下图）。 ▲图源“ASCO”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除同时，血清AFP（甲胎蛋白，原发性肝癌的特异性肿瘤标志物）水平从治疗前的80000ng/ml，骤降至1148.9ng/ml （CAR-T输注后第1个月）、 746.7ng/ml （CAR-T输注后第3个月）（详见下图）。 ▲图源“ASCO”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除（二）CAR-T治疗CD70肾细胞癌：疾病控制率可达100％ ALLO-316是一款新型抗CD70同种异体CAR-T细胞疗法，CD70基因在肾细胞癌（RCC）中高表达。故而ALLO-316在低剂量水平下的初步抗肿瘤活性和令人鼓舞的安全性表明，该疗法可能为接受过大量治疗的靶向CD70的透明细胞肾细胞癌（ccRCC）患者，提供一种新的希望与选择。2022年3月，ALLO-316被美国食品药品监督管理局（FDA）授予快速通道资格（FTD），用于难治性肾细胞癌（RCC）的治疗。 ALLO-316的1期TRAVERSE临床研究，共入组19例患者，其中10例确诊为 CD70靶向的难治性肾细胞癌（RCC）。入组接受淋巴细胞清除+ALLO-316回输治疗。结果显示：在18例可评估疗效的患者中，疾病控制率（DCR）高达89％。而在10例已知肿瘤表达CD70的患者中，疾病控制率（DCR）更是高达100％（详见下表）！ ▲数据源自“Allogene”，全球肿瘤医生网医学部整理汇总其中3例患者获得部分缓解（PR），最长的反应持续到第八个月，且CD70表达水平较高的患者，肿瘤缩小趋势更大。 ▲图源“Allogene”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除三、小编寄语 CAR-T细胞疗法早在12年前，就因挽救了一位急性淋巴细胞白血病患儿（Emily Whitehead）的生命，让其获得临床治愈，并存活至今而一战成名！如今，全球已有13款CAR-T细胞产品获批上市，为晚期血液肿瘤患者带来了一线生机。但CAR-T治疗实体瘤却一直是临床的老大难问题，值得欣慰的是，如今各国都已纷纷加入CAR-T研发大军中，并不断更新CAR-T技术、发现新的治疗靶点。尤其是本次《Nature》杂志报道的这项研究，让弥漫性中线神经胶质瘤患者的生存期，从中位11个月，最大提升至33个月，更有甚者肿瘤缩小率高达100%，再次让我们看到了攻克实体瘤的希望！想了解CAR-T、CAR-NK、TCR-T、TIL等国内外新型抗癌疗法更多讯息的患者，可将治疗经历、近期病理报告、近期影像学检查结果等资料，提交至全球肿瘤医生网医学部，初步评估病情，或了解详细的入排标准。四、参考资料 [1]Monje M,et al.Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas[J]. Nature, 2024: 1-8. https://www.nature.com/articles/s41586-024-08171-9 [2]Zhao Z,et al.An armored GPC3-directed CAR-T for refractory or relapsed hepatocellular carcinoma in China: A phase I trial[J]. 2021. https://meetings.asco.org/abstracts-presentations/199036/poster [3]https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-presents-interim-phase-1-data-allo-316 本文为全球肿瘤医生网原创，未经授权严禁转载

细胞疗法免疫疗法放射疗法临床结果ASH会议

2024-11-19

·GlobeNewswire-Health Care

Allogene Therapeutics Announces Participation in December Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in two upcoming investor conferences in December. The Company is also announcing that the presentation time for the upcoming Jefferies London Healthcare conference on November 20, 2024 has changed. TIME UPDATE: Jefferies London Healthcare ConferenceWednesday, November 20, 202411:30AM GMT/ 6:30AM ET The Citizens JMP Hematology and Oncology Summit (Virtual)Monday, December 2, 20248:00AM PT/11:00AM ET 36th Annual Piper Sandler Healthcare ConferenceTuesday, December 3, 20245:00AM PT/8:00AM ET Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company's website for approximately 30 days. About Allogene TherapeuticsAllogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X and LinkedIn. Cautionary Note on Forward-Looking Statements for AllogeneThis press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to our product candidates being based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factor” heading in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. AlloCAR T™ is a trademark of Allogene Therapeutics, Inc. Allogene Media/Investor Contact:Christine CassianoEVP, Chief Corporate Affairs & Brand Strategy OfficerChristine.Cassiano@allogene.com

细胞疗法免疫疗法

2024-11-18

·PipelineReview

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

SOUTH SAN FRANCISCO, CA, USA I November 18, 2024 I Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T ™ ) products for cancer and autoimmune disease, today announced preclinical data for ALLO-329, an investigational allogeneic CD19/CD70 dual CAR T cell therapy being evaluated as a treatment for autoimmune diseases. The data, presented at the American College of Rheumatology (ACR) Convergence 2024, demonstrate the potential of ALLO-329 to specifically address key challenges associated with current autologous CAR T cell therapies in development for patients with autoimmune disease and highlights the promise of an allogeneic CAR T to reset the immune system. ALLO-329 is the first CAR T designed to target both CD19+ B-cells and CD70+ activated T cells. Targeting of B cells has been shown to induce durable, treatment-free remissions in patients with certain autoimmune diseases. CD70 is expressed in activated T cells, which have been implicated in immune responses, including in autoimmunity. Simultaneous elimination of CD70+ T cells may enhance the therapeutic benefit and expand the list of addressable indications. CD70+ activated T cells also include alloreactive T-cells – the patient’s cells that would attack and reject an allogeneic CAR-T. ALLO-329 is designed to effectively eliminate alloreactive T-cells and render ALLO-329 resistant to rejection. Incorporation of Dagger ® technology into ALLO-329 is intended to reduce or eliminate lymphodepletion prior to cell infusion. “The CAR T space for autoimmune disease is highly competitive, with many approaches focusing only on isolated aspects of autoimmune pathogenesis,” said Zachary Roberts, M.D., Ph.D., EVP, Research and Development and Chief Medical Officer of Allogene. “What sets ALLO-329 apart is its ability to target a greater spectrum of immune dysfunction, addressing both B cells and activated T-cells involved in the disease process, potentially improving disease outcomes with reduced or even no lymphodepletion. Coupled with its “off-the-shelf” accessibility, ALLO-329 has the potential to meet the substantial needs of a broad patient population. These preclinical findings reinforce our excitement as we move this therapy toward clinical development across multiple autoimmune conditions.” Key findings from the preclinical evaluation of ALLO-329 include: Based on these promising preclinical results, the Company plans to file an investigational new drug (IND) application with the FDA in the first quarter of 2025 and expects to have proof-of-concept by year-end 2025. About ALLO-329 ALLO-329 is a CD19/CD70 dual AlloCAR T ™ investigational product being developed for the treatment of autoimmune diseases. ALLO-329 utilizes CRISPR-based site-specific integration for dual CAR expression. This approach targets both CD19+ B cells and CD70+ T cells, which play a role in autoimmune disease pathogenesis. Additionally, ALLO-329 incorporates Allogene’s clinically validated Dagger ® technology, designed to reduce or eliminate the need for lymphodepletion, a pre-treatment regimen that may be a significant barrier to CAR T cell therapy adoption in autoimmune indications. About Allogene Therapeutics Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T ™ ) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com , and follow @AllogeneTx on X and LinkedIn. SOURCE: Allogene Therapeutics

细胞疗法免疫疗法ASH会议AACR会议临床研究

100 项与 ALLO-316 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肾细胞癌	临床1期	美国	Allogene Therapeutics, Inc.	2021-02-24
CD70阳性肿瘤	临床前	美国	Allogene Therapeutics, Inc.	2024-12-01
急性髓性白血病	临床前	美国	Allogene Therapeutics, Inc.	2020-11-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04696731 (TRAVERSE, SITC2024) 人工标引	临床1期	转移性透明细胞性肾细胞癌	29	ALLO-316	醖衊鏇壓憲積簾獵鹹窪(壓窪積壓醖窪繭網顧醖) = 壓鹽膚範遞襯醖蓋築鹽醖範鏇醖築顧繭淵鏇窪 (廠觸夢鬱構壓製繭鹹衊 ) 更多	积极	2024-11-05
NCT04696731 (TRAVERSE, AACR2023) 人工标引	临床1期	转移性透明细胞性肾细胞癌末线	17	ALLO-316	遞鹽網鏇蓋糧蓋廠鏇鹹(醖觸鏇齋窪糧餘壓遞糧) = 鹹鬱襯壓範鏇遞蓋範鹹顧構選鏇簾鹹積鹽製築 (襯艱衊顧繭顧夢淵艱衊 ) 更多	积极	2023-04-14